ALKERMES | ALKS - Equity Capital And Reserves


ALKERMES reported $1.81B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Acadia Pharmaceuticals USD 1.25B 20.68M Mar/2026
ALKERMES USD 1.81B 57.02M Jun/2026
Amgen USD 9.19B 532M Mar/2026
Biogen USD 18.85B 196.3M Jun/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Coherus Biosciences USD 61.01M 26.76M Dec/2025
Eli Lilly USD 31.2B 4.66B Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
J&J USD 84.97B 3.78B Jun/2026
Malin Corporation EUR 193.2M 75M Dec/2024
Merck USD 45.88B 6.73B Mar/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Neurocrine Biosciences USD 3.69B 286.2M Jun/2026
Otsuka Holdings JPY 3.24T 131.63B Jun/2026
Ovoca Bio EUR 780K 485K Dec/2025
Pfizer USD 85.19B 4.91B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Vertex Pharmaceuticals USD 20.25B 886M Jun/2026